Real-world study evaluates CREXONT effects on motor fluctuations and “Good On” time in Parkinson’s patients, suggesting its potential benefit.
Evaluate interim outcomes from the real-world study of CREXONT, assessing its impact to extend “Good On” time and reduce “Off” time in PD patients after switching from other levodopa-based therapies.
No takes yet. Share an insight, caveat, or question.
Isaacson et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: